PLPRGHRAPEMEPN, corresponding to C terminal amino acids 180-193 of Human PUMA alpha. (Peptide available as ab9644.)
Apoptosis is related to many diseases and development. The p53 tumor-suppressor protein induces apoptosis through transcriptional activation of several genes. A novel p53 inducible pro-apoptotic gene was identified recently and designated PUMA (for p53 upregulated modulator of apoptosis) and bbc3 (for Bcl-2 binding component 3) in human and mouse (1-3). PUMA/bbc3 is one of the pro-apoptotic Bcl-2 family members including Bax and Noxa, which are also transcriptional targets of p53. The PUMA gene encodes two BH3 domain-containing proteins termed PUMA-a and PUMA-b (1). PUMA proteins bind Bcl-2, localize to the mitochondria, and induce cytochrome c release and apoptosis in response to p53. PUMA may be a direct mediator of p53-induced apoptosis.
Our Abpromise guarantee covers the use of ab9643 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||Use a concentration of 1 - 2 µg/ml. Detects a band of approximately 23 kDa.Can be blocked with Human PUMA peptide (ab9644). Use at a concentration of 1 - 2 µg/ml. Detects a band of approximately 23 kDa. Can be blocked with PUMA peptide (180/193) (ab9644). A lower band at approximately 16 kDa was detected in MOLT4 and U937 cells, which may represent the PUMA-beta form.|
|IHC-P||Use at an assay dependent concentration.|
|ICC/IF||Use a concentration of 1 µg/ml.|
Western blot analysis of PUMA expression in human (H) K562 and mouse (M) 3T3 cell lysates with anti-PUMA at 2